BioCardia, Inc. - Common Stock (BCDA)
Frequently Asked Questions About BioCardia, Inc. - Common Stock (BCDA)
How does BioCardia contribute to the community?
BioCardia contributes to the community by focusing on improving patient care and outcomes for those with heart disease. The company advocates for education on cardiovascular health and supports initiatives that aim to raise awareness about heart health and the importance of research in regenerative medicine.
How does BioCardia's research impact heart disease treatment?
BioCardia's research has the potential to significantly impact the treatment of heart disease by providing novel therapeutic options that utilize stem cells and regenerative technologies. The company's innovative approaches aim to repair damaged heart tissue, improve heart function, and enhance the quality of life for patients suffering from chronic heart conditions.
How is BioCardia funded?
BioCardia is funded through a combination of public offerings, private investments, and grants. The company actively seeks funding opportunities to support its ongoing research and development activities, enabling it to bring its innovative therapies to market effectively.
Is BioCardia publicly traded?
Yes, BioCardia, Inc. is a publicly traded company listed on the Nasdaq under the ticker symbol BCDA. Being a public company allows it to raise capital from a broader range of investors and provides greater visibility in the healthcare market.
What are BioCardia's key products?
BioCardia's key products include the CardiAMP Cell Therapy System, which is designed for the treatment of heart failure using autologous cardiac stem cells. The company also has other therapeutic applications in various stages of development, focused on regenerating heart tissue and improving heart function.
What are the future plans for BioCardia?
BioCardia plans to continue focusing on advancing its clinical programs and expanding its product portfolio in the field of regenerative medicine. The company aims to conduct further clinical trials to demonstrate the efficacy of its products and seek regulatory approvals to bring their therapies to market.
What clinical trials is BioCardia currently conducting?
BioCardia is currently conducting clinical trials focused on the efficacy and safety of its CardiAMP Cell Therapy System in patients with heart failure. These trials are essential for evaluating the therapeutic impact of the company's treatments and for obtaining necessary regulatory approvals.
What does BioCardia, Inc. do?
BioCardia, Inc. is a biotechnology company focused on developing and commercializing cell and regenerative therapies for heart disease. The company specializes in advanced cardiovascular products and aims to improve treatment outcomes for patients suffering from various heart conditions through innovative therapeutic solutions.
What is the company culture like at BioCardia?
The company culture at BioCardia emphasizes innovation, teamwork, and a patient-focused approach. Employees are encouraged to collaborate, share ideas, and contribute to the mission of advancing regenerative therapies to improve cardiovascular health.
What is the significance of the CardiAMP Cell Therapy System?
The CardiAMP Cell Therapy System represents a significant advancement in the treatment of heart failure through the use of a patient's own stem cells. This system is designed to recover damaged heart muscle and improve cardiac function, offering a potential breakthrough for patients who have limited treatment options.
What is the ticker symbol for BioCardia, Inc.?
The ticker symbol for BioCardia, Inc. is BCDA, and it is traded on Nasdaq. This symbol is used by investors and shareholders to track the company's stock performance in the stock market.
What is the vision of BioCardia?
BioCardia envisions a future where advanced regenerative therapies are accessible to patients suffering from heart disease, ultimately leading to improved treatment outcomes and enhanced quality of life. The company's commitment to research and innovation drives its mission to transform cardiovascular care.
What milestones has BioCardia achieved?
BioCardia has achieved several notable milestones, including successful interim results from clinical trials and collaborations with leading research institutions. These accomplishments validate their scientific approach and enhance their reputation in the biotech sector.
What partnerships does BioCardia have?
BioCardia has engaged in various partnerships with research institutions, clinical organizations, and other biotech firms to foster innovation and expedite the development of its products. These collaborations aim to leverage expertise and resources to enhance the effectiveness of clinical trials and therapeutic applications.
What regulatory challenges does BioCardia face?
As a biotechnology company, BioCardia faces regulatory challenges associated with the approval and commercialization of its products. Navigating the complex requirements of the FDA and other health regulatory bodies is crucial for successfully bringing their therapies to market and ensuring patient safety.
When was BioCardia, Inc. founded?
BioCardia, Inc. was founded in 1995, with the goal of addressing unmet clinical needs in the field of cardiology. Since its inception, the company has been dedicated to advancing the science of regenerative medicine and has made significant progress in developing technologies aimed at improving cardiovascular health.
Where is BioCardia located?
BioCardia is headquartered in San Carlos, California, which places it in close proximity to several leading research institutions, healthcare facilities, and a vibrant biotechnology community. This location supports collaboration and innovation in the fields of medicine and technology.
Who are BioCardia's competitors?
BioCardia faces competition from other biotechnology and pharmaceutical companies that focus on regenerative medicine and treatments for cardiovascular diseases. Notable competitors include companies developing stem cell therapies and cardiac-related products, which operate in the rapidly evolving field of cardiac regeneration.
Who is the management team at BioCardia?
BioCardia's management team consists of experienced professionals in the fields of biotechnology, medicine, and business. The team is led by co-founder and CEO Dr. Peter Altman, who brings extensive experience in product development, regulatory affairs, and strategic planning in the biotechnology sector.
What is the current price of BioCardia, Inc. - Common Stock?
The current price of BioCardia, Inc. - Common Stock is 2.200
When was BioCardia, Inc. - Common Stock last traded?
The last trade of BioCardia, Inc. - Common Stock was at 11:28 am EDT on April 3rd, 2025
What is the market capitalization of BioCardia, Inc. - Common Stock?
The market capitalization of BioCardia, Inc. - Common Stock is 47.56M
How many shares of BioCardia, Inc. - Common Stock are outstanding?
BioCardia, Inc. - Common Stock has 21.62M shares outstanding.